CHICAGO—While artificial intelligence is increasingly seen as a means of improving endoscopy, studies at Digestive Disease Week 2023 hinted at a potential flaw: It may not be as effective outside of the controlled environment of randomized trials, that is, in routine community practice.
“We did not see an increase in adenoma detection rate [ADR] with CADe [computer-aided detection] over baseline and saw no improvement in any performance tertile,” reported investigator Uri Ladabaum, MD, who presented results of one large study in the community setting. “There was also no significant difference between the outcomes of endoscopists in the CADe study sites and the control sites that did not use CADe. This was not what we expected to see and was, of course, disappointing,” added Dr. Ladabaum, a professor of medicine and the senior vice chief and director of the gastrointestinal cancer prevention program at Stanford University School of Medicine, in Palo Alto, Calif.